Amgen wins FDA approval of D-mab

Two months ahead of schedule and just days behind European regulators, the FDA has approved Amgen's denosumab for postmenopausal women with osteoporosis. Once the drug hits the market as Prolia, analysts expect that it will evolve into a multibillion-dollar franchise product--marking a key turning point for the world's biggest independent biotech. Patients will be able to get the two annual injections at a cost of about $1,650. At that price Amgen believes it can snare a significant chunk of...